Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04218916

Rhodiola Rosea for Coronary Microvascular Disease

The Efficacy and Safety of Rhodiola Rosea in Patients With Coronary Microvascular Disease

Sponsor: Qilu Hospital of Shandong University

Conditions Coronary Microvascular Disease

Interventions Placebo Rhodiola Rosea Capsules

Updated 5 times since 2020 Last updated: Jan 3, 2020 Started: Jan 31, 2020 Primary completion: Jan 31, 2021 Completion: Jan 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Coronary Microvascular Disease, this trial is ongoing. The trial is conducted by Qilu Hospital of Shandong University and has accumulated 5 data snapshots since 2020. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2_PHASE3
Feb 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qilu Hospital of Shandong University

Data source: Qilu Hospital of Shandong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.